COVID-19 VACCINE DECISION TREE

Primary Series

COVID-19 infection in the last 90 days?

Ages 0-4

No

Ages 5-11

No

Immune-compromised?\(^1\)

Yes

2 doses of Pfizer\(^2\), given at days 0 and 21

3 doses of Pediatric Pfizer\(^2\), given at days 0, 21, and 49

No

2 doses of Pfizer\(^2\), given at days 0 and 21

3 doses of Pfizer\(^2\), given at days 0, 21, and 49

Ages 12-17

Immune-compromised?\(^1\)

No

Yes

2 doses of Pfizer\(^2\), given at days 0 and 21

3 doses of Pfizer\(^2\), given at days 0, 21, and 49

Ages 18+

Immune-compromised?\(^1\)

No

Yes

Received COVID-19 monoclonal antibody treatment?

No

Defer any dose of COVID-19 vaccine for 90 days following monoclonal antibody treatment for COVID-19 disease

Yes

Currently infected?

No

Defer vaccine until released from isolation

Yes

Yes

No

2 doses of Pfizer\(^2\), given at days 0 and 21

3 doses of Pfizer\(^2\), given at days 0, 21, and 49

3 doses of Pfizer\(^2\), given at days 0, 21, and 49

OR

2 doses of Moderna\(^2\), given at days 0 and 28

3 doses of Moderna\(^2\), given at days 0, 28 and 56

OR

1 dose of Janssen\(^{2,3,4}\)

1 dose of Janssen\(^{2,3,4}\)
1 The CDC defines immune-compromised as individuals who have:
   - Been receiving active cancer treatment for tumors or cancers of the blood
   - Received an organ transplant and are taking medicine to suppress the immune system
   - Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
   - Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
   - Advanced or untreated HIV infection
   - Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

2 Primary series dose volumes are as follows:
   - Pediatric Pfizer (ages 5-11) 0.2mL
   - Pfizer (ages 12+) 0.3mL
   - Moderna 0.5mL
   - Janssen 0.5mL

3 It is recommended that all individuals should receive a booster dose of an mRNA COVID-19 vaccine (Pfizer or Moderna) two months after their Janssen (Johnson & Johnson) vaccine.

4 All individuals are recommended to receive a primary vaccination series and booster dose of an mRNA COVID-19 vaccine (Pfizer or Moderna) over the use of the Janssen (Johnson & Johnson) COVID-19 vaccine. This change in guidance comes after reviewing data finding an increased risk of Thrombosis with Thrombocytopenia associated with those who have received the Janssen COVID-19 vaccine.
All individuals are recommended to receive a primary vaccination series and booster dose of an mRNA COVID-19 vaccine (Pfizer or Moderna) over the use of the Janssen COVID-19 vaccine. This change in guidance comes after reviewing data finding an increased risk of Thrombosis with Thrombocytopenia associated with those who have received the Janssen COVID-19 vaccine.

Booster dose volumes are as follows:
- Pediatric Pfizer (ages 5-11) 0.2mL
- Pfizer (ages 12+) 0.3mL
- Moderna 0.5mL
- Janssen 0.5mL

For additional questions, please refer to the CDC guidelines on vaccine booster eligibility.

---

1 All individuals are recommended to receive a primary vaccination series and booster dose of an mRNA COVID-19 vaccine (Pfizer or Moderna) over the use of the Janssen COVID-19 vaccine. This change in guidance comes after reviewing data finding an increased risk of Thrombosis with Thrombocytopenia associated with those who have received the Janssen COVID-19 vaccine.

2 Booster dose volumes are as follows:
- Pediatric Pfizer (ages 5-11) 0.2mL
- Pfizer (ages 12+) 0.3mL
- Moderna 0.5mL
- Janssen 0.5mL

For additional questions, please refer to the CDC guidelines on vaccine booster eligibility.